{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:11:43Z","timestamp":1793913103743,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ratchadapisek Somphot Fund, Faculty of Medicine, Chulalongkorn University","award":["RA-MF-22\/67"],"award-info":[{"award-number":["RA-MF-22\/67"]}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["NRCT5-RSA63001-02"],"award-info":[{"award-number":["NRCT5-RSA63001-02"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24645-w","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:31:01Z","timestamp":1763548261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics and abbreviated AUC model of enteric-coated mycophenolate sodium in early kidney transplant recipients receiving tacrolimus"],"prefix":"10.1038","volume":"15","author":[{"given":"Tanat","family":"Lertussavavivat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatsanan","family":"Tanathitiphuwarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanyanuch","family":"Rakpithayanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwasin","family":"Udomkarnjananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thunyatorn","family":"Wuttiputhanun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somratai","family":"Vadcharavivad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyos","family":"Avihingsanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Eiam-ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kearkiat","family":"Praditpornsilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natavudh","family":"Townamchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"25","key":"24645_CR1","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl. J. Med. 357 (25), 2562\u20132575 (2007).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"24645_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/TP.0b013e318205568c","volume":"91","author":"AJ Langone","year":"2011","unstructured":"Langone, A. J., Chan, L., Bolin, P. & Cooper, M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 91 (4), 470\u2013478 (2011).","journal-title":"Transplantation"},{"issue":"21","key":"24645_CR3","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.2146\/ajhp040380","volume":"62","author":"GR Ingle","year":"2005","unstructured":"Ingle, G. R. & Shah, T. Enteric-coated mycophenolate sodium for transplant immunosuppression. Am. J. Health Syst. Pharm. 62 (21), 2252\u20132259 (2005).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"24645_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/TP.0b013e31822527ca","volume":"92","author":"F Ortega","year":"2011","unstructured":"Ortega, F. et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation 92 (4), 426\u2013432 (2011).","journal-title":"Transplantation"},{"issue":"1","key":"24645_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41598-018-20071-3","volume":"8","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Increased exposure of tacrolimus by co-administered mycophenolate mofetil: population pharmacokinetic analysis in healthy volunteers. Sci. Rep. 8 (1), 1687 (2018).","journal-title":"Sci. Rep."},{"issue":"11","key":"24645_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y Le Meur","year":"2007","unstructured":"Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transpl. 7 (11), 2496\u20132503 (2007).","journal-title":"Am. J. Transpl."},{"issue":"3","key":"24645_CR7","first-page":"120","volume":"17","author":"G Filler","year":"2004","unstructured":"Filler, G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl. Int. 17 (3), 120\u2013125 (2004).","journal-title":"Transpl. Int."},{"issue":"9","key":"24645_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/clinchem\/48.9.1497","volume":"48","author":"T Pawinski","year":"2002","unstructured":"Pawinski, T., Hale, M., Korecka, M., Fitzsimmons, W. E. & Shaw, L. M. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin. Chem. 48 (9), 1497\u20131504 (2002).","journal-title":"Clin. Chem."},{"issue":"4","key":"24645_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s11096-019-00848-w","volume":"41","author":"B Kulabusaya","year":"2019","unstructured":"Kulabusaya, B., Vadcharavivad, S., Avihingsanon, Y., van Gelder, T. & Praditpornsilpa, K. Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. Int. J. Clin. Pharm. 41 (4), 1047\u20131055 (2019).","journal-title":"Int. J. Clin. Pharm."},{"issue":"4","key":"24645_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/ki.2010.170","volume":"78","author":"P Lertdumrongluk","year":"2010","unstructured":"Lertdumrongluk, P. et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 78 (4), 389\u2013395 (2010).","journal-title":"Kidney Int."},{"issue":"6","key":"24645_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10928-014-9392-y","volume":"41","author":"W Jawie\u0144","year":"2014","unstructured":"Jawie\u0144, W. Searching for an optimal AUC estimation method: a never-ending task? J. Pharmacokinet. Pharmacodyn. 41 (6), 655\u2013673 (2014).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"10","key":"24645_CR12","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2019","unstructured":"Metz, D. K. et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation 103 (10), 2012\u20132030 (2019).","journal-title":"Transplantation"},{"issue":"4","key":"24645_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1600-6143.2006.01693.x","volume":"7","author":"K Budde","year":"2007","unstructured":"Budde, K. et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am. J. Transpl. 7 (4), 888\u2013898 (2007).","journal-title":"Am. J. Transpl."},{"issue":"2","key":"24645_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","volume":"4","author":"K Budde","year":"2004","unstructured":"Budde, K. et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. 4 (2), 237\u2013243 (2004).","journal-title":"Am. J. Transplant."},{"issue":"4","key":"24645_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/01.tp.0000251969.72691.ea","volume":"83","author":"K Budde","year":"2007","unstructured":"Budde, K. et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (4), 417\u2013424 (2007).","journal-title":"Transplantation"},{"issue":"12","key":"24645_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2165\/0003088-200847120-00007","volume":"47","author":"BC de Winter","year":"2008","unstructured":"de Winter, B. C. et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin. Pharmacokinet. 47 (12), 827\u2013838 (2008).","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"24645_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","volume":"4","author":"M Salvadori","year":"2004","unstructured":"Salvadori, M. et al. Enteric coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novorenal transplant patients. Am. J. Transplant. 4 (2), 231\u2013236 (2004).","journal-title":"Am. J. Transplant."},{"issue":"8","key":"24645_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1432-2277.2009.00877.x","volume":"22","author":"M Shehata","year":"2009","unstructured":"Shehata, M. et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl. Int. 22 (8), 821\u2013830 (2009).","journal-title":"Transpl. Int."},{"issue":"5","key":"24645_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/FTD.0b013e3181b8679a","volume":"31","author":"BC de Winter","year":"2009","unstructured":"de Winter, B. C. et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther. Drug Monit. 31 (5), 585\u2013591 (2009).","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"24645_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/FTD.0b013e318255cc15","volume":"34","author":"AI S\u00e1nchez Fructuoso","year":"2012","unstructured":"S\u00e1nchez Fructuoso, A. I. et al. Limited-sampling strategy for mycophenolic acid in renal transplant recipients reciving enteric-coated mycophenolate sodium and tacrolimus. Ther. Drug Monit. 34 (3), 298\u2013305 (2012).","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"24645_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","volume":"86","author":"T van Gelder","year":"2008","unstructured":"van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de Novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86 (8), 1043\u20131051 (2008).","journal-title":"Transplantation"},{"issue":"11","key":"24645_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1097\/TP.0b013e318234e134","volume":"92","author":"Y Le Meur","year":"2011","unstructured":"Le Meur, Y. et al. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation 92 (11), 1244\u20131251 (2011).","journal-title":"Transplantation"},{"issue":"7","key":"24645_CR23","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","volume":"9","author":"RS Gaston","year":"2009","unstructured":"Gaston, R. S. et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial. Am. J. Transpl. 9 (7), 1607\u20131619 (2009).","journal-title":"Am. J. Transpl."},{"issue":"4","key":"24645_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2125.2009.03612.x","volume":"69","author":"C Sommerer","year":"2010","unstructured":"Sommerer, C. et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br. J. Clin. Pharmacol. 69 (4), 346\u2013357 (2010).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2S1","key":"24645_CR25","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ajt.2025.01.020","volume":"25","author":"KL Lentine","year":"2025","unstructured":"Lentine, K. L. et al. OPTN\/SRTR 2023 annual data report: kidney. Am. J. Transpl. 25 (2S1), S22\u2013S137 (2025).","journal-title":"Am. J. Transpl."},{"issue":"5","key":"24645_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/FTD.0b013e3181858169","volume":"30","author":"JM Park","year":"2008","unstructured":"Park, J. M., Lake, K. D. & Cibrik, D. M. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. Ther. Drug Monit. 30 (5), 591\u2013596 (2008).","journal-title":"Ther. Drug Monit."},{"key":"24645_CR27","doi-asserted-by":"crossref","unstructured":"Suhail, S. M., Vathsala, A., Lou, H. X. & Woo, K. T. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients. Transplant Proc. 32(7):1757-8. (2000).","DOI":"10.1016\/S0041-1345(00)01388-9"},{"issue":"12","key":"24645_CR28","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1093\/ndt\/gfm468","volume":"22","author":"WP Yau","year":"2007","unstructured":"Yau, W. P., Vathsala, A., Lou, H. X. & Chan, E. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol. Dial Transpl. 22 (12), 3638\u20133645 (2007).","journal-title":"Nephrol. Dial Transpl."},{"issue":"10","key":"24645_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/tri.12382","volume":"27","author":"P Li","year":"2014","unstructured":"Li, P. et al. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transpl. Int. 27 (10), 994\u20131004 (2014).","journal-title":"Transpl. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24645-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24645-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24645-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T23:02:56Z","timestamp":1763938976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24645-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24645"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24645-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40653"}}